142 related articles for article (PubMed ID: 33865565)
21. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
[TBL] [Abstract][Full Text] [Related]
22. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
Uy HL; Reasner CA; Samuels MH
Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
[TBL] [Abstract][Full Text] [Related]
23. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature.
El Kawkgi OM; Ross DS; Stan MN
Clin Endocrinol (Oxf); 2021 Jul; 95(1):3-12. PubMed ID: 33283314
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine treatment for pediatric Graves' disease.
Ma C; Kuang A; Xie J; Liu G
Cochrane Database Syst Rev; 2008 Jul; (3):CD006294. PubMed ID: 18646146
[TBL] [Abstract][Full Text] [Related]
25. Histologic Findings and Cytological Alterations in Thyroid Nodules After Radioactive Iodine Treatment for Graves' Disease: A Diagnostic Dilemma.
El Hussein S; Omarzai Y
Int J Surg Pathol; 2017 Jun; 25(4):314-318. PubMed ID: 28201927
[TBL] [Abstract][Full Text] [Related]
26. An optimal treatment for pediatric Graves' disease is radioiodine.
Rivkees SA; Dinauer C
J Clin Endocrinol Metab; 2007 Mar; 92(3):797-800. PubMed ID: 17341574
[TBL] [Abstract][Full Text] [Related]
27. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
Li HX; Xiang N; Hu WK; Jiao XL
J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
[TBL] [Abstract][Full Text] [Related]
28. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
29. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.
Santos RB; Romaldini JH; Ward LS
Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
31. Radioactive iodine therapy in Graves' hyperthyroidism.
Sankar R; Sripathy G
Natl Med J India; 2000; 13(5):246-51. PubMed ID: 11190053
[TBL] [Abstract][Full Text] [Related]
32. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
33. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
35. Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease.
Dong QY; Li SJ; Gao GQ; Liu XM; Li WX; Liang CG; Du WH; Wsng YL
Clin Invest Med; 2011 Oct; 34(5):E262. PubMed ID: 21968267
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
[TBL] [Abstract][Full Text] [Related]
37. Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease.
Koroscil TM
South Med J; 1995 Aug; 88(8):831-6. PubMed ID: 7631208
[TBL] [Abstract][Full Text] [Related]
38. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves' disease.
Liu M; Jing D; Hu J; Yin S
Am J Med Sci; 2014 Oct; 348(4):288-93. PubMed ID: 24805788
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
Taprogge J; Gape PMD; Carnegie-Peake L; Murray I; Gear JI; Leek F; Hyer SL; Flux GD
Thyroid; 2021 Dec; 31(12):1829-1838. PubMed ID: 34598656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
